quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:40:18·3d
INSIDERFiling
KalVista Pharmaceuticals Inc. logo

SEC Form 4 filed by Palleiko Benjamin L

KALV· KalVista Pharmaceuticals Inc.
Health Care
Original source

Companies

  • KALV
    KalVista Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jan 9UpdateNeedham$35.00
  • Jan 6UpdateNeedham$32.00
  • Jan 31UpdateJMP Securities$19.00
  • Jan 7UpdateTD Cowen$30.00
  • Dec 18UpdateBofA Securities$22.00
  • Mar 11UpdateNeedham$42.00

Related

  • INSIDER3d
    SEC Form 4 filed by Audhya Paul K.
  • INSIDER3d
    SEC Form 4 filed by Sweeny Nicole
  • INSIDER3d
    SEC Form 4 filed by Piekos Brian
  • PR3d
    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
  • PR16d
    KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
  • PR21d
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • PR25d
    KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
  • INSIDER27d
    SEC Form 4 filed by Venrock Healthcare Capital Partners Iii, L.P.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022